Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Vertex Pharmaceuticals Incorporated Argus Buy 155
Stryker Corporation Argus Buy 120
Thermo Fisher Scientific, Inc. Argus Buy 145
Universal Health Services Inc. Barclays Buy 150
Mallinckrodt Public Limited Company Barclays Buy 80
Abbott Laboratories Barclays Buy 52
Regeneron Pharmaceuticals, Inc. Barclays Buy 593
Mylan N.V. Barclays Buy 57
Humana Inc. Barclays Buy 223
Cigna Corp. Barclays Buy 156
Intuitive Surgical, Inc. Barclays Buy 625
Biogen Inc. Bernstein Buy 360
Eli Lilly and Company BofA/Merrill Buy 90
Waters Corporation BofA/Merrill Buy 140
Aetna Inc. BofA/Merrill Buy 162
Amgen Inc. Deutsche Bank Buy 180
Allergan plc Deutsche Bank Buy 342
Boston Scientific Corporation Deutsche Bank Buy 22
Gilead Sciences Inc. Deutsche Bank Buy 124
St. Jude Medical Inc. Deutsche Bank Buy 77
1 2